Dr. Oh Discusses Choosing Abiraterone in Prostate Cancer
In Partnership With:
William K. Oh, MD, chief, Division of Hematology and Medical Oncology, professor of medicine and urology, Mount Sinai School of Medicine, explains when he would choose abiraterone acetate (Zytiga) for patients with prostate cancer.
William K. Oh, MD, chief, Division of Hematology and Medical Oncology, professor of medicine and urology, Mount Sinai School of Medicine, explains when he would choose abiraterone acetate (Zytiga) for patients with prostate cancer.
Abiraterone acetate has become a major player in the prostate cancer treatment landscape, as noted in a plenary session during the 2017 ASCO Annual Meeting.
Oh says that it is ultimately up to the patient, but price is a consideration, as it is an expensive therapeutic option.
